|Dr. Richard D. Klausner M.D.||Exec. Chairman||1.43M||N/A||1952|
|Ms. Elizabeth Homans||CEO & Director||1.14M||N/A||1966|
|Ms. Heather D. Turner||Chief Gen. Counsel & Sec.||917.08k||N/A||1973|
|Mr. Stephen J. Hill||Chief Operating Officer||722.58k||N/A||1970|
|Mr. Charles W. Newton||Chief Financial Officer||N/A||N/A||1971|
|Nellie Dillery||Director of Accounting||N/A||N/A||N/A|
|Mr. Richard Goold Ph.D.||Chief Information Officer||N/A||N/A||1960|
|Ms. Lisa Ryan||Chief People Officer||N/A||N/A||1967|
|Dr. Nicholas Restifo M.D.||Exec. VP of Research||N/A||N/A||1961|
|Ms. Elaine Cheung||Sr. VP of Corp. Strategy & Bus. Devel.||N/A||N/A||N/A|
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.